A meta-analysis of randomized controlled trials comparing coronary artery bypass graft with percutaneous transluminal coronary angioplasty: one- to eight-year outcomes
Stuart N. Hoffman, DO*,
John A. TenBrook, Jr, MD*,
Michael P. Wolf, MD*,
Stephen G. Pauker, MD, FACC* ,
Deeb N. Salem, MD, FACC* and
John B. Wong, MD*,*,1
* Department of Medicine, Division of Clinical Decision Making, Informatics, and Telemedicine, Boston, Massachusetts, USA
Division of Cardiology, Tufts-New England Medical Center, Boston, Massachusetts, USA
View larger version (23K):
[in a new window]
|
Figure 1 Risk difference for all-cause mortality for years 1, 3, 5, and 8 post-initial revascularization. All trials (A) and multivessel coronary artery disease (B). The lines represent 95% confidence intervals. Event rates for the coronary bypass arm at one, three, five, and eight years for all trials (A) were 3.0%, 4.7%, 7.1%, and 13.7%; for multivessel trials (B) were 3.4%, 5.3%, 8.9%, and 15.8%. CABG = coronary artery bypass graft surgery; PTCA = percutaneous transluminal coronary angioplasty.
|
|
View larger version (14K):
[in a new window]
|
Figure 2 Risk difference for subsequent revascularization comparing coronary artery bypass graft surgery (CABG) to percutaneous transluminal coronary angioplasty (PTCA) (± stents) for years 1 and 3. The lines represent 95% confidence intervals. For trials with stents, numbers of patients and trials are adjacent to data at one and three years. Year 5 and 8 data were available only for CABG versus PTCA without stent.
|
|
View larger version (12K):
[in a new window]
|
Figure 3 Risk difference for all-cause mortality for years 4 and 6.5 post-initial revascularization comparing coronary artery bypass graft surgery (CABG) to percutaneous transluminal coronary angioplasty (PTCA) for diabetic and non-diabetic patients. The lines represent 95% confidence interval.
|
|
|
